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Abstract
OBJECTIVE:
Objective of this systematic review is to determine whether or not OPT-80 is a safe and effective
treatment for patients with C.difficile infection.
STUDY DESIGN:
Review of three English language primary studies published between 1996 and the present.
DATA SOURCES:
Randomized, controlled clinical trials analyzing safety and efficacy of OPT-80 were found using
MEDLINE, OVID, COCHRANE, and PubMed databases.
OUTCOMES MEASURED:
Each of the three trials measured different outcomes. The main outcomes measured were:
adverse effects of OPT-80, clinical cure of C.diff infection, diarrhea resolution by day ten,
diarrheal resolution by day ten without the use of additional treatment, and the rate of recurrence
of infection.
RESULTS:
The Phase I trial reported only mild adverse events. It indicated that no significant side effects
occurred after taking OPT-80 in healthy individuals supporting the further clinical development
of OPT-80 as an oral therapy for C.diff infection. The Phase 2a dose finding trial demonstrated a
decreased time to resolution of diarrhea, and increased rate of complete relief from symptoms of
infection with increasing doses of OPT-80, as well as, a low rate of recurrence with OPT-80 at
all dosing levels. The other Phase 2a trial compared prevention of recurrence between OPT-80
treatment groups and vancomycin treatment groups and revealed a lower percent of patients with
recurrence in the OPT-80 group with statistical significance.
CONCLUSIONS:
The results of the three clinical trials show that the use of OPT-80 is safe and effective in
reducing symptoms of C.difficile infection. It was effective in reducing time to resolution of
diarrhea and successful in preventing recurrence. The low incidence of side effects to OPT-80
macrocylic antibiotic make it a promising alternative to the current regime of vancomycin or
metronidazole for the treatment of C.difficile infection.
KEY WORDS:
Clostridium difficile, OPT-80
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Introduction
C.difficile colitis is an infection of the colon caused by the bacteria Clostridium difficile in
people whose normal bowel flora have been replaced or disrupted by recent antibiotic use.
Clostridium difficile is a Gram-positive, anaerobic, spore-forming rod that produces toxins that
cause an inflammatory reaction to occur in the large intestine. The infection causes the patient to
have multiple watery stools per day, abdominal cramping and distension, leukocytosis, and a
low-grade fever. Challenges with C.difficile infection are that the widespread use of broadspectrum antibiotics is leading to the incidence to rise, and with the current treatment regimen,
the rate of recurrence after initial therapy is now up to 20%. This paper evaluates three
randomized controlled trials that compare OPT-80 to placebo or to the standard antibiotic
treatments for C.difficile infection.
Clostridium difficile (C.diff) colitis is a substantial problem for many hospital, long-term
care, and elderly patients in the community. C.diff infections are the most common cause of
nosocomial diarrhea in developed countries. Approximately 300,000 new cases of C.diff
infection occur annually in the US. (7) They have been attributable to a mortality rate of 7.5% in
some regions in Europe and North America. Health-related costs for people afflicted by C.diff
are significant and in some instances in excess of $4,000/case. (3) There is a need to find a more
effective alternative treatment to oral vancomycin that will cost less, pose less concern for abuse
and resistance, and create a lower chance of relapse. (1)
C.diff colonizes the GI tract after the normal gut flora are altered by antibiotic use, and this
bacteria release toxins that cause intestinal tissue damage worsening symptoms. The
inflammatory response created causes increased vascular permeability leading to the watery
diarrhea. There has been increasing incidence of infection due to the emergence of a new
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virulent strain of Clostridium that is antimicrobial resistant and also has increased rates of
recurrence. This new epidemic strain has led to a more serious disease course, an increase in
complicated toxic megacolon, and an increased in C.diff related deaths. It is known that all
antibiotics can cause C.diff infection, but it is not known why only 2/3rds of colonized patients
are asymptomatic. (7) Populations at risk are patients with prolonged hospital stays, patients
older than 65 years, undergoing broad-spectrum antibiotic use, and patients with other medical
conditions or GI disorders.
This infection should be treated immediately. The current methods followed for the
treatment of C.diff include: stopping the causative antibiotic use (if all antibiotic use cannot be
discontinued, ampicillin, second and third generation cephalosporins, clindamycin, and
fluoroquinolones should be avoided in the patient’s treatment), starting the patient on
metronidazole 500mg po TID or IV every 6-8hrs x 10-14 days, or vancomycin 125 mg po QID x
10-14 days.
The use of OPT-80 for the treatment of C.diff infection is being proposed because the
above treatment regimens of metronidazole are becoming less effective than treatment with
vancomycin and because both antibiotic therapies have a high rate of disease recurrence. OPT80 displays narrow antimicrobial activity with excellent activity against C.diff and is inactive
against gram-negative organisms so it spares the normal gut flora.
Objective
The objective of this systematic review is to determine whether or not OPT-80 is a safe and
effective treatment for C.difficile infection. Previous and current randomized, controlled trials
have determined that OPT-80, an 18-membered macrocyclic antibiotic that is poorly absorbed
but has high levels of activity in the gut, and has a limited spectrum of activity against

Shupp, OPT-80 C.difficile colitis

4

Clostridial species. (1) It can be an effective and safe alternative treatment for patients
experiencing colitis caused by Clostridium difficile.
Methods
All three studies selected for this review meet the following specific criteria. The
population and problem must consist of males and females 18 years of age with diarrhea culture
positive for C.diff infection and the intervention used must be OPT-80. The two treatment
comparisons in these studies were placebo versus OPT-80 and vancomycin versus OPT-80. The
main outcomes measured were: clinical cure, diarrhea resolution by day ten, diarrheal resolution
by day ten without the use of additional treatment, and the rate of recurrence of infection. The
types of studies selected are: Phase 2A open-label trial, Double blind placebo controlled phase 1
study, and Dose finding, randomized open label study.
A detailed search was completed by the author using search engines: OVID/MEDLINE,
COCHRANE, and PubMed. Articles were selected based on relevance and based on the fact that
the outcomes of the studies mattered to patients. (Patient Oriented Evidence that Matters, or
POEMs) Key words used to search for articles: “C.difficile infection”, “OPT-80”. All articles
selected were published in English and were published in peer-reviewed journals. Studies that
were included were articles published between the years 1996 – the present, and were conducted
in a randomized, controlled, and prospective view. Excluded studies that did not meet criteria
were read for content and data only and were not included in calculations. Under these criteria,
three randomized control clinical trials were identified and are included in this review. Table 1
includes the demographics and characteristics of the included studies. A summary of statistics
reported or used are P-values, RR, OR, ARR, ABI, RRR, RBI, NNT, RRI, ARI, NNH.
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Louie,
Emery
2009

Louie,
Miller
2009

Shue
2008

Table 1 - Demographics & Characteristics of included studies
#Pts
Age
Inclusion
Exclusion
W/D
(yr)
Criteria
Criteria
Open Label
38
>18 3+ diarrheal
12+ stools,
3
Phase 2A
stools/d or
Vomiting, Ileus,
trial
6+ in 36hr and
severely tender
(+) C.diff
abdomen, WBC
> 30x10e9 c/L,
Toxic
megacolon,
IBD, Pts with 1+
therapies
Dose finding,
49
>18 3+ diarrheal
12+ stools,
0
Randomized
stools/d or
Vomiting, Ileus,
Open Label
6+ in 36hr and
severely tender
study
(+) C.diff
abdomen, WBC
Treatment naïve
> 30x10e9 c/L,
or only trt with
Toxic
vancomycin,
megacolon,
metronidazole for IBD, Pts with 1+
<24hrs
therapies
Dbl blind
Ph1A 18- Healthy, non1
Phase1 study
= 16,
65 smoker, non-drug
abuser, BMI
Ph1B
18.5-29.9, with
= 24
written consent
Type
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Interventions
OPT-80 for
treatment of
C.diff infection
50, 100, 200 mg
groups

OPT-80 for
treatment of
C.diff infection
50, 100, 200 mg
groups

OPT-80 for the
treatment of
C.diff infection

Outcomes measured
Outcomes used for analysis addressed safety and tolerance of OPT-80, clinical cure,
diarrheal resolution, decreased infection with C.diff, and rate of recurrence. Shue et al measured
if OPT-80 was safe and tolerable by measuring adverse events in healthy individuals. Louie,
Miller et al evaluated clinical cure based on the resolution of diarrheal stools and cessation of
abdominal pain within ten days of treatment and based on no additional need for treatment
following the ten day therapy. Resolution of diarrhea was measured by decrease in frequency of
> 3 to < 2 semi-formed to formed stools per day. Louie, Emery et al measured clinical response
based on the same criteria as Louie, Miller et al stated above. They measured in vivo activity of
OPT-80 decreasing infection of C.diff by measuring spore counts. Secondary outcome measures
were different in the three studies. Louie, Miller et al measured rate of recurrence. A positive
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recurrence was measured by a recurrence of >3 unformed stools/day and (+) culture of C.diff
within 6 to 8 weeks after treatment. Louie, Emery et al determined recurrence of C.diff colitis by
measuring spore count and toxin level within 28 days post treatment.
Results
Three controlled trials presented in this review analyzed OPT-80 a macrocycle antibiotic
used to treat C.diff colitis in patients that met the inclusion criteria presented in Table 1. These
trials investigated data with intention to treat analysis and studied participants diagnosed with
C.diff infection or healthy individuals in order to determine safety and tolerance of
aforementioned medication. Results pertaining to the primary outcomes of cure of infection and
safety of intervention were presented in dichotomous data in all three studies.
In the Shue et al Phase 1B-multidose, double blind study, tolerability and pharmacokinetics
of oral doses of OPT-80 in 24 healthy individuals were evaluated. (6) Three groups of 8
subjects, equally male and female, were given either 150, 300, and 450 mg OPT-80 daily for 10
consecutive days. At each dose level, volunteers were randomized to receive active drug or
placebo. Tolerability and safety of OPT-80 were evaluated based on adverse-event (AE) reports,
vital signs, EEG, and clinical lab values. Two major adverse events were reported in the 450mg
group and 5 in the placebo group. (Table 2) Because data was presented in dichotomous format,
statistical analysis of these results reveal that the relative risk increase (RRI) was -60%, the
absolute risk increase (ARI) of the study drug is -37.5%, and the number of pts needed to cause
harm (NNH) was -3. These results show significance, but it was found that all adverse events
were mild, and none were considered to be drug related.
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Table 2 – AEs in OPT-80 vs. Placebo in Safety, Tolerability Study. (Shue et al)
Number
AE
Description of AE
RR
RRI
ARI
NNH
in study
OPT-80
450mg

2

Headache, URI sxs

8

-2.66
0.4
-60%
- 37.5%
URI sxs, fatigue,
=-3
Placebo
5
nasal congestion,
8
rash, pruritis
AE = adverse events, RR = risk ratio, RRI = relative risk increase, ARI = absolute risk increase, NNH =
numbers needed to harm

Louie, Miller et al reported a Phase 2A dose-finding, randomized, open-label study to
select a safe and effective dose of OPT-80 for the treatment of mild to moderate C.diff colitis.
Patients at least 18 years of age, equally male and female, with three or more diarrheal stools per
day or six or more diarrheal stools in a 36hr period and with a positive C.diff toxin result were
randomized to receive increasing dosages of OPT-80. Patients were randomized to receive either
50, 100, or 200mg of OPT-80 every 12 hours for 10 days and were monitored for 6 weeks after
completion of treatment to evaluate for relapse or recurrence. If patients failed to clinically
improve or have resolution of diarrhea within 4 days of treatment, they were placed on
alternative treatment and were declared a failure. (4) The primary outcome variables for
measurement were clinical cure of diarrhea, total relief of symptoms, time to resolution of
diarrhea. Secondary outcome variable was the recurrence of C.diff infection. Fourteen, 15, and
16 subjects in the 100-, 200-, and 400-mg/day groups, respectively, were evaluated for clinical
outcomes.
Table 3 summarizes the rates of clinical cure, complete relief of symptoms, and rates of
clinical recurrence between the lowest dosing group (100mg) and the highest (400mg) and the
statistical analysis of the dichotomous data pertaining to this information. Clinical cure rate and
complete relief of symptoms responses did not reach statistical significance because the grouping
size was small. (4) The OPT-80 100mg group showed a 71% clinical cure rate and 37.5% had
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complete relief of symptoms within treatment period. The OPT-80 400mg treatment group
showed a 94% clinical cure rate and 86.7% showed complete relief of symptoms. The number
needed to treat was calculated for clinical cure as 5 patients and for complete relief of symptoms
as 3 patients. In both groups, 1 patient had recurrence of C.diff toxin present and cultivable
bacteria from stool samples. The number needed to treat for clinical recurrence was calculated at
-118 patients.
Table 3 – Data analysis of clinical cure rate, complete relief of symptoms, and clinical recurrence in
the population treated per protocol (Louie, Miller et al)
= # of patients in the following groups showing
cure, symptom relief, recurrence / total number
in group (%)
100mg OPT- 400mg OPTRR
RBI
ABI
NNT
80
80
Clinical cure*
10/14 (71%)
15/16 (94%)
1.313
31.25%
22.3%
4.48 = 5
Complete
13/15
2.03
relief of
6/16 (37.5%)
2.312
131.2%
49.2%
(86.7%)
=3
symptoms**
RR
RRR
ARR
NNT
Clinical
1/14
1/16
-117.65
0.88
-11.97%
-0.85%
recurrence***
(8.3%)
(6.3%)
= -118
* = Diarrhea resolution by day 10 ** = Resolution to <3 bowel movements per day that were solid or
semi-formed without associated sxs of Fever, abdominal pain, increased WBC count by day 10 of
treatment. *** = Recurrence defined as presence of toxin-positive diarrhea within 6 weeks after treatment
RR = relative risk, RBI = relative benefit increase, ABI = absolute benefit increase, NNT = number
needed to treat

Louie, Miller et al described the time to resolution of diarrhea as the time for the patient to
resolve to 1 or 2 unformed stools per day. The median time to resolution of diarrhea (days)
standard deviation was 6.3 3.7 days and 3.6 2.0 days for the 100- and 400-mg groups
respectively. The difference between the 100- and 400-mg/day treatment groups approached
statistical significance with a p-value = 0.0506.
In the Louie, Emery et al Phase 2A open label trial patients were randomized to receive
50mg, 100mg, or 200mg of OPT-80 orally every 12 hrs for 10 days. After the completion of this
study, eight additional comparable patients with C.diff infection received vancomycin 125mg
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four times a day for 10 days as a standard treatment control. Stool samples were obtained at
study entry date and at 4, 10, 14, 21, 28, and 42 days. C.diff cytotoxin B titers and spore counts
were determined from all samples. Results are displayed in Table 4 below. The authors
compared day 21 and day 28 mean spore counts (mean SD [95% CI]) for vancomycin controls
(3.6 2.0 [2.4-4.7]) vs. OPT-80 100mg treatment group (2.3 0.9 [1.8-2.7], p= 0.04). Results
were similar for reemergence of toxins, showing it to be more likely following vancomycin
treatment. ARR for reemergence of toxins and spores in stool comparing OPT-80 100mg to
vancomycin control was -3.75% and -25.0%, in that order. NNT for reemergence of toxins and
spores was -3 and -4, respectively, for OPT-89 versus vancomycin treatment
Table 4 – Prevention of recurrence of C.difficile infection in OPT-80 treatment group vs.
vancomycin control groups (Louie, Emery et al)
Number of pts
Number of
RR
RRR
ARR
NNT
with (+) C.diff
pts with
Toxin
Toxin
Toxin
Toxin
spores in
(+)cytotoxin
RRR
ARR
NNT
stool/ total pts
B in stool/
RR Spore
a
Spore
Spore
Spore
total pts b
OPT-80
100mg

3/8

0/8

vanco
control

5/8

3/8

0
0.6

-100%

-3.75%

-2.66 =
-3

-40.0%

-25.0%

-4

a

= compared to patients treated with OPT-80 100mg, reappearance of C.diff spores in stool was more
likely following vancomycin treatment (p value = 0.04 with CI of 95%) b = compared to all OPT-80
patients, reappearance of C.diff cytotoxin B appeared to be more likely following vancomycin treatment
(p value = 0.03 with CI of 95%)

Discussion
Largely, these authors show that OPT-80 is well tolerated after oral administration in
healthy individuals, caused a significant clinical cure rate, relief of symptoms, and successfully
prevented recurrence in patients that were suffering from C.difficile infection. OPT-80 was
tested for safety and tolerability in the Shue et al study and it was found that no serious adverse
events occurred, but there were mild side effects reported. Based on calculations the RR of 0.4

9
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shows that the risk of having an adverse event while taking the experimental drug was less than
the risk of having an adverse event in the placebo group. The ARI showed that there was a
negative risk of having a bad event; meaning, participants were less likely to have an AE in the
treatment group. Although this is significant information, it was later determined that these mild
adverse events were not related to the use of the study drug.
OPT-80 was shown to resolve diarrhea and disease within 10 days of treatment, and it was
achieved at 71% and 94% of patients in the 100mg and 400mg treatment groups in the Louie,
Miller study. The response between treatment groups was not statistically different due to the
small sample group sizes. With each increase in dose of OPT-80, the time to resolution of
diarrhea decreased, and there was no reported increase in any side of effects of medication at the
increased doses. There were two subjects in the 100mg treatment group were declared clinical
failures because they did not meet the 6 day limit for response to treatment. It is unknown
whether a longer time limit to show response to OPT-80 would have resulted in a different
outcome and decreased limitations of this study.
The Louie, Miller et al study demonstrated that the ABI for clinical cure was 22.3% and for
49.2% for complete relief of symptoms when comparing the 100-mg group to the 400-mg group.
Revealing that there was a 22.3% increase of having a benefit (clinical cure) by taking 400-mg of
OPT-80 per day versus taking the 100-mg and that there was 49.2% increase in relief of
symptoms in the 400-mg group over the 100-mg treatment group. Rapidity of resolution of
diarrhea, or clinical cure, and completeness of symptom control was in favor of the highest dose
group, 400-mg OPT-80 over the 100-mg/day group. The NNT defines how much effort is
needed to achieve one beneficial outcome. One would only need to treat 5 patients to attain 1
with clinical cure and 3 patients to attain 1 with complete relief of symptoms using the data from
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the Louie, Miller study.
The low recurrence rates seen in both treatment groups are supportive of the possibility that
OPT-80 is selective and that it allows normal flora of the bowel to re-establish itself following
the treatment of C.diff infection preventing another bout of colitis and diarrhea. The ARR was
calculated for prevention showing that there was -0.85% absolute decrease when using OPT-80
at the higher dosage over 100mg group. This was not a very large decrease between the two
dosage groups; however, the importance lies in the fact that the recurrence rate itself was low in
all treatment groups (both less than 10%).
Recurrence was also researched in the Louie, Emery et al trial. Only 3 of 8 patients
showed recurrence of spores in their stool in the OPT-80 treatment group compared to 5 in the
vancomycin group. And 0 of 8 patients had toxin in their stool compared to 3 in the vancomycin
standard group. Even though spore counts and toxin levels were measured, the outcome of
prevention of re-infection was established and was still a PICO and could be evaluated. These
values are of great importance because the results show statistical significance with a p-value of
0.03 for recurrence of toxin and 0.04 for recurrence of spores. The RRs for recurrence were both
negative meaning that the experimental group was less likely to have any recurrence (spore or
toxin positive) of C.diff infection than the control group. A negative NNT value meant for every
3 patients (toxin) or 4 patients (spore) who took OPT-80 100mg, there was one fewer incidence
of C.diff infection with toxin or spores, respectively, than in the group that was taking
vancomycin. Lower post-treatment spore and toxin counts imply a comparative or more
beneficial ecologic effect by OPT-80 as a treatment option for C.diff infection.
More studies have been done recently further comparing OPT-80 to the metronidazole and
vancomycin, so that a more direct comparison between OPT-80 can be made. Recently in the
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US, OPT-80 has been granted fast track status by the FDA because it has showed promise in
treating C.difficile infection, for which no other drug works as well, in order to get this new drug
to patients sooner.
Conclusion
It is concluded that OPT-80 is a safe and effective alternative treatment for the patient with
Clostridium difficile infection. This was proven through the numerous significant reductions and
or improvements in C.diff infection symptoms through the three studies sampled. The studies
reported upon had smaller treatment groups and had limited number of treatment concentrations.
There has been more recent data in a Phase IIb/III trial and Phase III clinical trial describing the
effects of OPT-80, now called Fidaxomicin, versus vancomycin. Researchers have increased
sample sizes in these trials and increased the number of dosing groups. Before the development
of OPT-80, the only licensed medications that had documented effectiveness for this disease
remained metronidazole and vancomycin and both of these drugs had high recurrence rates
following therapy.
The morbidity, mortality, cost, and physical burden of C.diff infections are large. The rate
of recurrence has a significant health impact in patients and can occur more than one time in a
patient treated with the standard of care. This makes the use of OPT-80 for the treatment of
C.diff infection very striking. OPT-80 is the first new therapy for C.diff infection to show
clinical relevance, significant efficacy, and significant effects on preventing recurrence.
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